6IZC

Crystal structure of the chromosome-encoded beta-lactamase of Vibrio parahaemolyticus

6IZC の概要

• エントリーDOI: 10.2210/pdb6izc/pdb
• 分子名称: Beta-lactamase, SULFATE ION, PENTAETHYLENE GLYCOL, ... (4 entities in total)
• 機能のキーワード: vibrio, beta-lactamase, hydrolase
• 由来する生物種: Vibrio parahaemolyticus
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 61047.00

構造登録者

Ma, Q.,Li, P. (登録日: 2018-12-19, 公開日: 2019-12-25, 最終更新日: 2024-11-13)

主引用文献

Li, P.,Liu, C.,Li, B.,Ma, Q.
Structural analysis of the CARB beta-lactamase from Vibrio parahaemolyticus facilitates application of the beta-lactam/ beta-lactamase inhibitor therapy.
Biochimie, 171-172:213-222, 2020

PubMed Abstract: β-Lactams are the most widely used antibiotics in treating bacterial infections. However, they are rarely applied in infections caused by Vibrio parahaemolyticus, as the bacterium is intrinsically resistant to penicillins by expressing β-lactamase. Here we report structural characterization of the CARB β-lactamase from V. parahaemolyticus (CARB-20). CARB-20 is a class A β-lactamase, belonging to subclass A1 (containing 70STFKAL75, 130SDNTAANL137, 164RXEXXLN170, 231VGDKTG236, etc.), group LSBL2 (with the disulfide bridge C77-C123, motif 231IADRSGAG238 and R244). CARB-20 adopts a typical subclass A1 β-lactamase fold consisting of two domains. Its active site is constituted by four conserved motifs, similar to that of known subclass A1 β-lactamases. Analysis of the active site structure reveals its substrate preference for penicillin, ampicillin and carbenicillin but not for latterly developed cephalosporins. Meanwhile, β-lactamase inhibitors such as clavulanate and sulbactam can well fit into the active site, supporting β-lactams combined with β-lactamase inhibitors as a potential approach for treating infection of V. parahaemolyticus. The residues around the active site show certain variations, which can be useful for specific inhibitor design. In the directed evolution experiment, CARB-20 exhibited plasticity in developing significant resistance to inhibitors by accumulated residue substitutions. Therefore, careful monitoring of enzyme mutations is necessary for successfully applying β-lactam/β-lactamase inhibitor combination therapy. Taken together, our results open up an avenue of inhibitor design targeting vibrio β-lactamases, facilitating the application of β-lactams in treating vibrio infections.

PubMed: 32179166
DOI: 10.1016/j.biochi.2020.03.011

実験手法

X-RAY DIFFRACTION (1.55 Å)